Cryptococcosis therapeutic - Collaborations Pharmaceuticals
Latest Information Update: 28 Feb 2024
At a glance
- Originator Collaborations Pharmaceuticals
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cryptococcosis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Cryptococcosis in USA
- 06 Jan 2020 Cryptococcosis therapeutic is available for licensing as of 06 Jan 2020. http://www.collaborationspharma.com/pipeline